🇺🇸 Menactra in United States

93 US adverse-event reports

Marketing authorisation

FDA

• Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 27 March 2025 – 27 March 2026
• Total reports: 93

Most-reported reactions

1. Fatigue — 16 reports (17.2%)
2. Pain — 10 reports (10.75%)
3. Product Storage Error — 10 reports (10.75%)
4. Pyrexia — 10 reports (10.75%)
5. Chronic Kidney Disease — 9 reports (9.68%)
6. Cough — 8 reports (8.6%)
7. Headache — 8 reports (8.6%)
8. Pneumonia — 8 reports (8.6%)
9. Abdominal Pain — 7 reports (7.53%)
10. Anxiety — 7 reports (7.53%)

Source database →

Frequently asked questions

Is Menactra approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Menactra in United States?

National Institute of Allergy and Infectious Diseases (NIAID) is the originator. The local marketing authorisation holder may differ — check the official source linked above.